Clinigen Group signs agreement to divest its UK compounding business for £7.75 million

LONDON, UK: Clinigen Group plc announced the disposal of its non-core UK Specials manufacturing and Aseptic compounding business to Target Healthcare Ltd for a total consideration of up to £7.75 million. The compounding business sourced and manufactured specific unlicensed medicines referred to as ‘specials’ in a range of formulations for supply across the UK market…

Synairgen and Clinigen sign agreement for treatment of hospitalised patients with COVID-19

SOUTHAMPTON: Synairgen plc and Clinigen Group have signed an agreement to launch a Managed Access Program for Synairgen’s inhaled formulation of interferon beta (IFN-beta), SNG001, in the UK and the EU for the treatment of hospitalised COVID-19 patients.   SNG001 is an inhaled formulation of IFN-beta for direct delivery to the lungs via nebulisation. Synairgen announced…